Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Gastroenterology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Colon Cancer Clinical Trials

A listing of Colon Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (192) clinical trials

Is the Distance of Patients From Rouen University Hospital Influencing the Time Between Colectomy and First Chemotherapy Cure for Colon Cancer?

This project has for objective to demonstrate that the increase of the distance "Patient home center of treatment" may be associated with significant, other noticeable, noted events. This distance may also be available in the Rouen University Hospital. The study of the association in this distance and the delay in ...

Phase N/A

The Implication of Plasma ctDNA Methylation Haplotypes in Detecting Colorectal Cancer and Adenomas

Colorectal cancer (CRC) is the third most common cancer worldwide, the second deadliest cancer in the United States. DNA methylation is a commonly used biomarker for non-invasive CRC detection in plasma. The low sensitivity of blood-based tests is due to several limitations of detecting ctDNA in early-stage cancer. We developed ...

Phase N/A

Dynamic Monitoring of ctDNA Methylation to Predict Relapse in Stage II-III Colorectal Cancer After Radical Resection

At present, the main treatment of stage II-III CRC (CRC) is surgical resection. CRC patients after radical surgery have good overall survival. However, there are still a large number of patients with postoperative recurrence. The postoperative recurrence rate of stage II CRC patients is 20-30%, and that of stage III ...

Phase N/A

TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer

TACE is indicated for the treatment of unresectable CRC_LM, patients who are refractory to systemic chemotherapy, elderly, or have a poor performance status, and is usually performed using irinotecan (IRI) covalently loaded onto embolics. Although chemoembolization with irinotecan-loaded embolics results in an objective response, this method creates a hypoxic micro-environment. ...

Phase N/A

ZETA : Prospective Observational Study

Inclusion criteria All patients expected to be treated with aflibercept in combination with FOLFIRI for a mCRC, after failure of treatment with oxaliplatin + anti-EGFR on the decision of the doctor (situation included in the framework of the MA of aflibercept) . Age 18 years Signature of the agreement for ...

Phase N/A

The CLiFF Study: Change in Liver Function and Fat in Pre-operative Chemotherapy for Colorectal Liver Metastases

Obesity is the second most common cause of cancer in the United Kingdom (UK) and bowel cancer is the third most common cancer. Obesity can increase both the chance of developing bowel cancer and it's progression. Increased liver fat is likely to be important in this process, but it is ...

Phase N/A

Tumor Bank for Blood Samples

Recent progress in diagnosis and therapy of cancer diseases can be ascribed mainly to translational research. The relevance of "translational oncology" will only increase in the future -"From bench to bedside" - the swift implementation of new science research results in clinical studies in order to expedite progress in clinical ...

Phase N/A

Circulating Tumor DNA Analysis to Optimize Treatment for Patients With Colorectal Cancer

INTRODUCTION Colorectal cancer (CRC) is the third most common cancer worldwide. Approximately two-thirds of patients initially present with potentially curable disease but in spite of curatively intended treatment 30-40% experience relapse of disease. When diagnosed, survival of CRC can basically be improved in two ways, 1) by reducing the risk ...

Phase N/A

An Evaluation of a Multi-target Stool DNA (Mt-sDNA) Test Cologuard for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now

Subjects aged 45-49 at average risk for development of CRC will be enrolled. Subjects will complete the mt-sDNA test (Cologuard) followed by completion of a screening colonoscopy.

Phase N/A

Genomic Investigation of Unusual Responders

Studies have shown that tumors from the same patient may respond very differently to the same therapeutic agents. This study aims to investigate the genetic basis of tumors that respond abnormally well or poorly to therapeutic agents in an effort to understand the fundamental genetic basis of this response. The ...

Phase N/A